# Qualitative Evaluation: Hexavalent Vaccine - Indicator 2.2

**Vaccine:** Hexavalent  
**Category:** 2. BENEFITS OF THE INTERVENTION  
**Question:** 2.2 Efficacy and effectiveness estimates (e.g. against infection, disease, hospitalization, death), including in different populations  
**Evaluator:** Gemini 2.0 Flash Experimental  
**Date:** January 9, 2026

---

## Evaluation Results

**1. Core Conclusion Check:**
The AI and Human agree that the vaccine is effective against Pertussis, Hib, and Hepatitis B. However, they diverge significantly regarding Diphtheria, Tetanus, and Polio. The Human concludes these are effective based on immunogenicity data, whereas the AI explicitly claims "no efficacy/effectiveness estimates... were provided" for these three diseases.

**2. Contradiction Screen:**

- **Major Conflict (Diphtheria, Tetanus, Polio):** The Human Answer accurately cites seroprotection rates (e.g., "100% seroprotection" for Tetanus/Polio, "Nearly all" for Diphtheria) drawn from Sources 3, 4, 5, and 7. The AI states: *"No efficacy/effectiveness estimates... were provided in the extracted evidence."* This is a false negative. In vaccinology, when clinical efficacy trials are rare or unethical (as with Tetanus), immunogenicity is the standard estimate for effectiveness. The AI failed to recognize this data, directly contradicting the Human's findings.
- **Pertussis/Hib:** The AI provides *clinical* endpoints (vaccine effectiveness against disease), whereas the Human provides *immunological* endpoints (antibody levels). These are not contradictory; in fact, the AI's data here is arguably stronger (demonstrating actual disease reduction), but it fails to mention the antibody comparisons (e.g., non-inferiority) that the Human highlights.

**3. Evidence Overlap:**

- **Minimal numeric overlap:** The Human relies almost exclusively on **Immunogenicity** (Seroprotection/Seroconversion %), while the AI relies almost exclusively on **Clinical Effectiveness** (Vaccine Effectiveness (VE) % / Incidence reduction).
- **Pertussis:** Human cites 94–95% seroconversion; AI cites 97.2% protection and 85% efficacy. (Aligned).
- **Hib:** Human cites 96–100% antibody levels; AI cites 90–100% effectiveness. (Aligned).

**4. Final Verdict:** **Conflicting/Contradictory**

*Reasoning:* While the AI provided excellent clinical real-world data for Pertussis and Hib (exceeding the Human answer in that specific area), it failed to recognize immunogenicity (antibody titers) as a valid proxy for efficacy/effectiveness. Consequently, it falsely claimed that **no estimates existed** for Diphtheria, Tetanus, or Polio, despite the sources (and the Human Answer) containing abundant data on seroprotection rates for these diseases. This is a critical failure in source interpretation that leads to a direct contradiction with the ground truth.

---

## Key Insights

### Critical Failure
The AI demonstrated a fundamental misunderstanding of vaccinology evidence hierarchy by failing to recognize **immunogenicity data (seroprotection rates)** as valid proxies for efficacy/effectiveness in diseases where clinical trials are unethical or impractical.

### Strength
The AI successfully extracted and synthesized **clinical effectiveness data** for Pertussis and Hib, providing real-world disease reduction metrics that complement (though do not replace) the immunogenicity data.

### Recommendation
The evidence extraction prompt should explicitly instruct the LLM to recognize:
- Seroprotection/seroconversion rates as valid effectiveness proxies
- The evidence hierarchy in vaccine research (clinical > immunological > preclinical)
- That absence of clinical trial data does not mean "no evidence"
